Previous studies have demonstrated that PI3K inhibition amplifies IFNγ-mediated anti-tumour responses by downregulating PD-L1 [77], suggesting a potential combinatorial strategy for future investigations with SFV/IFNγ and anti-PD-L1. Here, CD274 is linked to neoplasm.